Items tagged with Scientific research
The key to treating TB may be in a common carbohydrate. What we know so far (post)
Curdlan is a popular carbohydrate in the food industry. Its name is derived from the word “curdle”, and as it suggests, it’s widely used as a thickener and stabiliser in everything from sausages to milk substitutes.
Tufts scientists use artificial intelligence to improve TB treatments (post)
Imagine you have 20 new compounds that have shown some effectiveness in treating a disease like tuberculosis (TB), which affects 10 million people worldwide and kills 1.5 million each year. You know that to treat the disease effectively, patients will need a combination of three or four drugs because TB bacteria behave differently in different environments—and in some cases, evolve to become drug-resistant.
A big step toward treating TB without risking antibiotic resistance (post)
Tuberculosis, an infectious disease that killed 1.5 million people in 2020, is most commonly treated with a cocktail of four drugs that must be taken for up to six months. This treatment plan, however, can have the unintended consequence of leading to antibiotic resistance, both because people may not finish the full course of treatment and, more directly, because one of the drugs can act on bacteria other than Mycobacterium tuberculosis, including components of the intestinal microflora that are critical to health and wellbeing.
Webinar: Mycobacterium tuberculosis complex lineages diversity and impact on TB treatment approaches (post)
The London School of Hygiene & Tropical Medicine will host a webinar on 12 October 2022 that will explore how host and bacteria differences may affect the response to TB treatment, and will present a novel patented technology to improve the study of the impact of Mycobacterium tuberculosis lineages differences on TB treatment response.
Scientists reveal protein mechanism behind TB pathogen success (post)
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), remains a leading infectious threat to public health worldwide. It is estimated to have infected 2–3 billion people and causes ~1.5 million deaths each year.
Merck and the Bill & Melinda Gates Medical Research Institute announce licensing agreement for novel TB antibiotic candidates (post)
RAHWAY, N.J., and Cambridge M.A., October 18, 2022 – Merck, (NYSE: MRK), known as MSD outside of the United States and Canada, and the Bill & Melinda Gates Medical Research Institute (Gates MRI) today announced a licensing agreement for two preclinical antibacterial candidates for evaluation as potential components of combination regimens for the treatment of tuberculosis (TB). These candidates were discovered by Merck scientists as part of the TB Drug Accelerator (TBDA). The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB. The initiative was established with support and leadership from the Bill & Melinda Gates Foundation.
Adapsyn Bioscience receives funding to discover novel therapeutics for TB (post)
HAMILTON, ON, Oct. 18, 2022 - Adapsyn Bioscience Inc., a chemical bioinformatics company that discovers novel drug-like small molecules, today announced that it has received funding from the Bill & Melinda Gates Foundation to find novel therapeutics that target tuberculosis (TB). Globally, TB remains a leading cause of death from infectious disease, and factors such as a growing resistance to current drug therapies have created an urgent need for new treatments to combat its spread. Adapsyn's discovery platform integrates artificial intelligence and machine learning to identify and isolate novel drug-like metabolites from microbes for downstream evaluation and development. Adapsyn will utilize the full capabilities of its platform to identify novel small molecules that inhibit established and emerging targets in Mycobacterium tuberculosis, the causative agent of the disease, which will help fuel the development of next-generation anti-TB drugs. The company will collaborate with leaders in TB research on target selection, bioactivity testing, and target confirmation.
Diversifying the next generation of TB vaccines (post)
SAN ANTONIO (October 17, 2022) – Mirroring the all-hands-on-deck collaborative approach that accelerated the development of a variety of COVID-19 vaccines during the pandemic, the National Institutes of Health is seeking to spark similar innovation for a longstanding, intractable disease: tuberculosis. As part of this national push, NIH’s National Institute of Allergy and Infectious Diseases awarded Texas Biomedical Research Institute (Texas Biomed) and The Access to Advanced Health Institute (AAHI) in Seattle, Washington, a $3.5 million, five-year Innovation for Tuberculosis Vaccine Discovery grant.
PBD Biotech raises further £2.4m for its breakthrough TB blood test (post)
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease; although treatable, there remains a global unmet need to diagnose the disease at an earlier stage and to identify carriers that may develop the disease. To address these objectives, PBD Biotech has developed a rapid screening blood test that shows promise for identifying people with the disease as well as a subgroup with pre-clinical infection at higher risk of developing the disease, offering the potential to revolutionise management of TB. The company has raised follow-on funding of £2.4M to support further clinical trials.
University of Oxford study provides important insights into TB correlates of protection (post)
Researchers from the University of Oxford have reported findings from a study that investigated whether previously identified correlates of protection associated with risk of full-blown tuberculosis (TB) disease could also be associated with risk of infection from the bacteria that causes TB - highlighting certain correlates in the process.
Page 62 of 74 · Total posts: 0
←First 61 62 63 Last→